NCT06479811

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2025-08-19Est. Completion: 2029-01-01

Enrollment target: 120 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Jessica K Turnerjessica.turner@nih.gov (240) 858-7554

Frank I Lin, M.D.frank.lin2@nih.gov (240) 760-6166

Other microbiome trials you might be interested in

A Feasibility Study of AI-Assisted Physiotherapy for Oral Cancer PatientsRecruiting

AI (Artificial Intelligence)Oral Cancer

This study aims to evaluate the feasibility, safety, and acceptability of a newly developed artificial intelligence (AI)…

Taipei, TaiwanEst. completion May 31, 2027

View Trial →

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2Recruiting

Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.